News

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...
Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...
In addition, HHS Secretary Robert F. Kennedy Jr addressed the delay in Novavax's approval in a CBS interview earlier this ...
WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is ...